Local medtech company launches surgical innovation

MedTech News: Sydney medical technology company’s surgical innovation has now been approved for launch in an international market.

Next Science’s XPerience No Rinse Antimicrobial Solution enters the market as a single step application where the residual solution remains in the surgical site after closure and continues to help defend against pathogens for several hours, giving surgeons a simple and effective adjunct to help prevent surgical site and post-operative infections.

Managing Director, Judith Mitchell commented “With market leading performance in pathogen reduction where bacteria like MRSA (“Golden Staph”) can be eliminated so that less than 1 bacterium in a hundred million is present, we expect the product will become a first choice in the battle to reduce surgical site infection (SSI).

“With an estimated 234 million surgical procedures undertaken globally per annum, XPerience provides an enormous opportunity to help reduce infection, antimicrobial resistance and save lives while reducing expenses for health systems arising from postsurgical infections.”

You may also like Johnson & Johnson leader reveals story behind winning top spot on Best Places to Work list

The solution is designed for use in virtually every open surgery with an initial focus on shoulder, hip, knee, trauma and podiatry, Next Science said.

Sales of XPerience will begin immediately in the US using a third-party distribution network following the US Food and Drug Administration (FDA) clearance, the company said.

The company has four products on the market, for treating chronic wounds, acne and for use in surgeries, but launching the XPerience solution is the company’s biggest priority for the year. The company raised $8 million for the launch last year.